Therefore, prior to treatment, archival tumor tissue or fresh tumor biopsies were tested for the biomarker 1 (LRRC19 > IGFBP2) and/or biomarker 2 (PIK3CA mutant) to determine eligibility for the study in CLIA-approved space. This evidence concerns the gene LRRC19 and neoplasm.